Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond ...

Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex ...

Black Diamond Therapeutics, Inc. ( (BDTX) ) has released its Q3 earnings. Here is a breakdown of the information Black Diamond Therapeutics, ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest ...

On Tuesday, Black Diamond Therapeutics (NASDAQ:BDTX) shares maintained its Buy rating and $11.00 price target from H.C. Wainwright. The biotechnology company, focused on precision... On Monday, TD ...

seekingalpha.com reported 2024-10-08 that Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from ...

In head-to-head comparisons with firmonertinib, zipalertinib, lazertinib and BDTX-1535, ORIC-114 has superior kinome selectivity with no off-target kinase liabilities identified. Shows complete ...

seekingalpha.com reported 2024-10-08 that Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from ...